Evidence map›Paper›PMID 19443804›Full record

ArticleStroke2009

eNOS mediates TO90317 treatment-induced angiogenesis and functional outcome after stroke in mice.

Jieli Chen, Xu Cui, Alex Zacharek, Cynthia Roberts, Michael Chopp

Open access · bronzeAbstract read
In one paragraph

Article in Stroke, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 45 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. LXR agonism for CNS diseases: promises and challenges.Journal of neuroinflammation · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Cholesterol in the retina: the best is yet to come.Progress in retinal and eye research · 2014
    Review
  18. Article
  19. Article
  20. Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE(-/-) mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jieli ChenDepartment of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA. jieli@neuro.hfh.edu
Xu Cui
Alex Zacharek
Cynthia Roberts
Michael Chopp
Oakland University · US

Funding

PREDICTION OF HUMAN BRAIN INFARCTION BY MRIP01NS023393 · NINDS · HENRY FORD HOSPITAL · PI ZHANG, ZHENG GANG · 1986 to 2011
$11.0M
Neurorestorative therapy of stroke with agents that increase HDLR01AG031811 · NIA · HENRY FORD HEALTH SYSTEM · PI CHEN, JIELI · 2009 to 2013
$1.4M
Neurorestorative Therapy of Stroke with StatinsR01NS047682 · NINDS · HENRY FORD HEALTH SYSTEM · PI CHEN, JIELI · 2004 to 2007
$1.0M
Imaging of Brain Remodeling and Functional RecoveryP50NS023393 · NINDS · HENRY FORD HEALTH SYSTEM · PI CHOPP, MICHAEL · 2007 to 2007
$882k
NIA NIH HHS R01 AG031811NINDS NIH HHS P01 NS023393NINDS NIH HHS P01 NS23393NINDS NIH HHS P50 NS023393NINDS NIH HHS R01 NS047682
6 · The paper itself

Abstract

background and purposeTO901317, a synthetic liver X receptor agonist, elevates high-density lipoprotein cholesterol (HDL-C) in mice. We tested the hypothesis that TO901317 treatment of stroke promotes angiogenesis and vascular maturation and improves functional outcome after stroke by increasing endothelial nitric oxide synthase (eNOS) phosphorylation.

methodsC57BL/6J mice were subjected to middle cerebral artery occlusion and were treated with or without TO901317 (30 mg/kg) starting 24 hours after middle cerebral artery occlusion and daily for 14 days.

resultsTO901317 significantly increased serum HDL-C level, promoted angiogenesis and vascular stabilization in the ischemic brain, and improved functional outcome after stroke. The increased HDL-C level significantly correlated with functional recovery after stroke. TO901317 also increased eNOS phosphorylation in the ischemic brain. Mechanisms underlying the TO901317-induced angiogenesis were investigated using eNOS knockout (eNOS-/-) mice. TO901317 treatment of eNOS-/- mice significantly increased HDL-C level but failed to increase angiogenesis and functional outcome after stroke. In vitro studies demonstrated that TO901317 and HDL-C significantly increased capillary tube formation and promoted eNOS phosphorylation activity in cultured mouse brain endothelial cells compared with nontreatment controls. However, TO901317 and high-density lipoprotein treatment-induced capillary tube formation were absent in eNOS-deficient mouse brain endothelial cell.

conclusionsThese data indicate that TO901317 treatment increases serum HDL-C level, which promotes angiogenesis through eNOS and leads to improvement of functional outcome after stroke.

Indexed as

AnimalsBenzenesulfonamidesCholesterol, HDLDisease Models, AnimalDNA-Binding ProteinsFluorocarbonsHydrocarbons, FluorinatedInfarction, Middle Cerebral ArteryLiver X ReceptorsMaleMiceMice, Inbred C57BLMice, KnockoutNeovascularization, PhysiologicNitric Oxide Synthase Type IIIOrphan Nuclear ReceptorsBenzenesulfonamidesCholesterol, HDLDNA-Binding ProteinsFluorocarbonsHydrocarbons, FluorinatedLiver X ReceptorsNitric Oxide Synthase Type IIIOrphan Nuclear ReceptorsReceptors, Cytoplasmic and NuclearSulfonamidesT0901317

Identifiers

PMID19443804
PMCPMC2724074
OpenAlexW2007363852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.